[Psychiatric symptoms of Huntington's disease].
Psychiatrische Symptome der Huntington-Krankheit.
Behavioral symptoms
Mental health
Nonpharmacological therapy
Pharmacological therapy
Psychotherapy
Journal
Der Nervenarzt
ISSN: 1433-0407
Titre abrégé: Nervenarzt
Pays: Germany
ID NLM: 0400773
Informations de publication
Date de publication:
30 Aug 2024
30 Aug 2024
Historique:
accepted:
30
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
30
8
2024
Statut:
aheadofprint
Résumé
Huntington's disease (HD) is an autosomal dominant inherited disease, which leads to motor, cognitive and psychiatric symptoms. The diagnosis can be confirmed by genetic testing for extended CAG repeats in the Huntingtin gene. Mental and behavioral symptoms are common in HD and can appear several years before the onset of motor symptoms. The psychiatric symptoms include apathy, depression, anxiety, obsessive-compulsive symptoms and, in some cases, psychoses and aggression. These are currently restricted to symptomatic treatment as disease-modifying treatment approaches are still under investigation. The current clinical practice is based on expert opinions as well as experience with the treatment of similar symptoms in other neurological and mental health diseases. This article provides an overview of the complex psychiatric manifestations of HD, the diagnostic options and the established pharmacological and nonpharmacological treatment approaches. Die Huntington-Krankheit (HK) ist eine autosomal-dominante Erbkrankheit, die zu motorischen, kognitiven und psychiatrischen Symptomen führt. Die Diagnose kann durch den molekulargenetischen Nachweis einer verlängerten CAG-Wiederholung im Huntingtin-Gen gesichert werden. Psychische und Verhaltenssymptome sind bei der HK häufig und können Jahre vor den motorischen Symptomen auftreten. Zu den psychiatrischen Symptomen gehören Apathie, Depression, Angst, Zwangssymptome und in einigen Fällen Psychosen und Aggression. Diese können aktuell nur symptomatisch behandelt werden, da sich krankheitsmodifizierende Therapieansätze bei der HK noch in der Erprobung befinden. Die derzeitige klinische Praxis basiert auf Expertenmeinungen sowie Erfahrung mit der Behandlung ähnlicher Symptome bei anderen neurologischen und psychiatrischen Krankheiten. In diesem Artikel geben wir einen Überblick über die komplexen psychischen Manifestationen der HK, die diagnostischen Möglichkeiten und die etablierten pharmakologischen und nichtpharmakologischen Behandlungsansätze.
Autres résumés
Type: Publisher
(ger)
Die Huntington-Krankheit (HK) ist eine autosomal-dominante Erbkrankheit, die zu motorischen, kognitiven und psychiatrischen Symptomen führt. Die Diagnose kann durch den molekulargenetischen Nachweis einer verlängerten CAG-Wiederholung im Huntingtin-Gen gesichert werden. Psychische und Verhaltenssymptome sind bei der HK häufig und können Jahre vor den motorischen Symptomen auftreten. Zu den psychiatrischen Symptomen gehören Apathie, Depression, Angst, Zwangssymptome und in einigen Fällen Psychosen und Aggression. Diese können aktuell nur symptomatisch behandelt werden, da sich krankheitsmodifizierende Therapieansätze bei der HK noch in der Erprobung befinden. Die derzeitige klinische Praxis basiert auf Expertenmeinungen sowie Erfahrung mit der Behandlung ähnlicher Symptome bei anderen neurologischen und psychiatrischen Krankheiten. In diesem Artikel geben wir einen Überblick über die komplexen psychischen Manifestationen der HK, die diagnostischen Möglichkeiten und die etablierten pharmakologischen und nichtpharmakologischen Behandlungsansätze.
Identifiants
pubmed: 39212681
doi: 10.1007/s00115-024-01728-z
pii: 10.1007/s00115-024-01728-z
doi:
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Huntington G, Chorea O (1872) The Medical and Surgical Reporter. S.W. Butler, Philadelphia
Huntington’s disease Collaborative Research, G. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72(6):971–983
doi: 10.1016/0092-8674(93)90585-E
Lee JM et al (2012) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78(10):690–695
pubmed: 22323755
pmcid: 3306163
doi: 10.1212/WNL.0b013e318249f683
Gardiner SL et al (2019) Prevalence of Carriers of Intermediate and Pathological Polyglutamine Disease–Associated Alleles Among Large Population-Based Cohorts. JAMA Neurol 76(6):650
pubmed: 30933216
doi: 10.1001/jamaneurol.2019.0423
Pringsheim T et al (2012) The incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis. Mov Disord 27(9):1083–1091
pubmed: 22692795
doi: 10.1002/mds.25075
Bates GP et al (2015) Huntington disease. Nat Rev Dis Primers 1(1):15005
pubmed: 27188817
doi: 10.1038/nrdp.2015.5
Tabrizi SJ et al (2022) A biological classification of Huntington’s disease: the Integrated Staging System. Lancet Neurol 21(7):632–644
pubmed: 35716693
doi: 10.1016/S1474-4422(22)00120-X
Paoli R et al (2017) Neuropsychiatric Burden in Huntington’s Disease. Brain Sci 7(12):67
pubmed: 28621715
pmcid: 5483640
doi: 10.3390/brainsci7060067
Paulsen et al (2014) Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study. Front Aging Neurosci 6:78
pubmed: 24795630
pmcid: 4000999
doi: 10.3389/fnagi.2014.00078
Stout JC et al (2012) Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington’s disease. J Neurol Neurosurg Psychiatry 83(7):687–694
pubmed: 22566599
doi: 10.1136/jnnp-2011-301940
van der Burg JMM et al (2021) Effect of Body Weight on Age at Onset in Huntington Disease. Neurol Genet 7(4):e603
pubmed: 34250226
pmcid: 8265577
doi: 10.1212/NXG.0000000000000603
Bachoud-Lévi AC et al (2019) International Guidelines for the Treatment of Huntington’s Disease. Front Neurol 10:710
pubmed: 31333565
pmcid: 6618900
doi: 10.3389/fneur.2019.00710
Rosas HD et al (2008) Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain 131(Pt 4):1057–1068
pubmed: 18337273
doi: 10.1093/brain/awn025
Vonsattel J‑P et al (1985) Neuropathological Classification of Huntington’s Disease. J Neuropathol Exp Neurol 44(6):559–577
pubmed: 2932539
doi: 10.1097/00005072-198511000-00003
Thu DC et al (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington’s disease. Brain 133(4):1094–1110
pubmed: 20375136
doi: 10.1093/brain/awq047
Martínez-Horta S et al (2018) Structural and metabolic brain correlates of apathy in Huntington’s disease. Mov Disord 33(7):1151–1159
pubmed: 29676484
doi: 10.1002/mds.27395
van Wamelen DJ et al (2013) Suprachiasmatic nucleus neuropeptide expression in patients with Huntington’s Disease. Sleep 36(1):117–125
pubmed: 23288978
pmcid: 3524533
Singh-Bains MK et al (2019) Cerebellar degeneration correlates with motor symptoms in Huntington disease. Ann Neurol 85(3):396–405
pubmed: 30635944
pmcid: 6590792
doi: 10.1002/ana.25413
Dorsey ER (2013) Natural History of Huntington Disease. JAMA Neurol
van Duijn et al (2014) Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry 85(12):1411–1418
pubmed: 24828898
doi: 10.1136/jnnp-2013-307343
Orth M et al (2010) Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY. PLoS Curr 2:Rrn1184
pubmed: 20890398
Anderson KE et al (2018) Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders. J Huntingtons Dis 7(4):355–366
pubmed: 30040737
pmcid: 6294590
doi: 10.3233/JHD-180293
McAllister B et al (2021) Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease. Neurology 96(19):e2395–e2406
pubmed: 33766994
pmcid: 8166441
doi: 10.1212/WNL.0000000000011893
Jellinger KA (2024) The pathobiology of depression in Huntington’s disease: an unresolved puzzle. J Neural Transm
van Duijn E, Kingma EM, van der Mast RC (2007) Psychopathology in verified Huntington’s disease gene carriers. J Neuropsychiatry Clin Neurosci 19(4):441–448
pubmed: 18070848
doi: 10.1176/jnp.2007.19.4.441
Kachian ZR et al (2019) Suicidal ideation and behavior in Huntington’s disease: Systematic review and recommendations. J Affect Disord 250:319–329
pubmed: 30875675
doi: 10.1016/j.jad.2019.03.043
Nock MK et al (2008) Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry 192(2):98–105
pubmed: 18245022
pmcid: 2259024
doi: 10.1192/bjp.bp.107.040113
Kenwood MM, Kalin NH, Barbas H (2022) The prefrontal cortex, pathological anxiety, and anxiety disorders. Neuropsychopharmacology 47(1):260–275
pubmed: 34400783
doi: 10.1038/s41386-021-01109-z
van Duijn et al (2008) Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington’s disease compared with mutation-negative first-degree relatives. J Clin Psychiatry 69(11):1804–1810
pubmed: 19026253
doi: 10.4088/JCP.v69n1116
Eddy CM, Parkinson EG, Rickards HE (2016) Changes in mental state and behaviour in Huntington’s disease. Lancet Psychiatry 3(11):1079–1086
pubmed: 27663851
doi: 10.1016/S2215-0366(16)30144-4
Abdollah Zadegan S et al (2023) Frequency and Pathophysiology of Apathy in Huntington Disease: A Systematic Review and Meta-Analysis. J Neuropsychiatry Clin Neurosci 35(2):121–132
pubmed: 36353818
doi: 10.1176/appi.neuropsych.20220033
Levy R, Dubois B (2006) Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 16(7):916–928
pubmed: 16207933
doi: 10.1093/cercor/bhj043
Pagonabarraga J et al (2015) Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 14(5):518–531
pubmed: 25895932
doi: 10.1016/S1474-4422(15)00019-8
De Paepe AE et al (2021) Gray Matter Vulnerabilities Predict Longitudinal Development of Apathy in Huntington’s Disease. Mov Disord 36(9):2162–2172
pubmed: 33998063
doi: 10.1002/mds.28638
Misiura MB et al (2019) Apathy Is Related to Cognitive Control and Striatum Volumes in Prodromal Huntington’s Disease. J Int Neuropsychol Soc 25(5):462–469
pubmed: 30806337
pmcid: 6711382
doi: 10.1017/S1355617719000067
Andrews SC et al (2021) Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington’s disease. Psychol Med 51(8):1338–1344
pubmed: 32063235
doi: 10.1017/S0033291720000094
Oosterloo M et al (2019) Obsessive-Compulsive and Perseverative Behaviors in Huntington’s Disease. J Huntingtons Dis 8(1):1–7
pubmed: 30714966
pmcid: 6398547
doi: 10.3233/JHD-180335
Hoffmann R et al (2019) Obsessive-Compulsive Symptoms are Less Common in Huntington’s Disease than Reported Earlier. J Huntingtons Dis 8(4):493–500
pubmed: 31424414
doi: 10.3233/JHD-190351
Karagas NE, Rocha NP, Stimming EF (2020) Irritability in Huntington’s Disease. J Huntingtons Dis 9(2):107–113
pubmed: 32417789
pmcid: 7369067
doi: 10.3233/JHD-200397
Simpson J et al (2019) Validity of irritability in Huntington’s disease: A scoping review. Cortex 120:353–374
pubmed: 31401402
doi: 10.1016/j.cortex.2019.06.012
Pardina-Torner H et al (2024) Disentangling the neurobiological bases of temporal impulsivity in Huntington’s disease. Brain Behav 14(3):e3335
pubmed: 38450912
pmcid: 10918610
doi: 10.1002/brb3.3335
McLauchlan DJ, Linden DEJ, Rosser AE (2022) Excessive response to provocation rather than disinhibition mediates irritable behaviour in Huntington’s disease. Front Neurosci 16:993357
pubmed: 36643017
pmcid: 9836783
doi: 10.3389/fnins.2022.993357
McCusker E, Loy CT (2014) The many facets of unawareness in huntington disease. Tremor Other Hyperkinet Mov 4:257
doi: 10.5334/tohm.231
Rossi M et al (2020) Nosology and Phenomenology of Psychosis in Movement Disorders. Mov Disord Clin Pract 7(2):140–153
pubmed: 32071931
pmcid: 7011839
doi: 10.1002/mdc3.12882
Bonelli RM, Hofmann P (2004) A review of the treatment options for Huntington’s disease. Expert Opin Pharmacother 5(4):767–776
pubmed: 15102562
doi: 10.1517/14656566.5.4.767
Cardoso F (2014) Differential diagnosis of Huntington’s disease: what the clinician should know. Neurodegen Dis Manage 4(1):67–72
doi: 10.2217/nmt.13.78
Saft C et al (2023) Differential diagnosis of chorea (guidelines of the German Neurological Society). Neurol Res Pract 5(1):63
pubmed: 37993913
pmcid: 10666412
doi: 10.1186/s42466-023-00292-2
Huntington Study Group (1996) Unified Huntington’s disease rating scale: Reliability and consistency. Mov Disord 11(2):136–142
doi: 10.1002/mds.870110204
Mason SL et al (2018) Predicting clinical diagnosis in Huntington’s disease: An imaging polymarker. Ann Neurol 83(3):532–543
pubmed: 29405351
pmcid: 5900832
doi: 10.1002/ana.25171
Zeun P et al (2019) Fluid and imaging biomarkers for Huntington’s disease. Mol Cell Neurosci 97:67–80
pubmed: 30807825
doi: 10.1016/j.mcn.2019.02.004
Saft C et al (2022) S2k-Leitlinie Chorea/Morbus Huntington. Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (DGN)
Gendiagnostikgesetz, Gesetz über genetische Untersuchungen bei Menschen (Gendiagnostikgesetz – GenDG) vom 31. Juli 2009 (BGBl. I S. 2529, 3672), das zuletzt durch Artikel 15 Absatz 4 des Gesetzes vom 4. Mai 2021 (BGBl. I S. 882) geändert worden ist. 31.07.2009: Ein Service des Bundesministeriums der Justiz sowie des Bundesamts für Justiz – www.gesetze-im-internet.de .
Macleod R et al (2013) Recommendations for the predictive genetic test in Huntington’s disease. Clin Genet 83(3):221–231
pubmed: 22642570
doi: 10.1111/j.1399-0004.2012.01900.x
Mühlbäck A et al (2023) What we don’t need to prove but need to do in multidisciplinary treatment and care in Huntington’s disease: a position paper. Orphanet J Rare Dis 18(1):19
doi: 10.1186/s13023-023-02622-8
Gelderblom H et al (2017) Bupropion for the treatment of apathy in Huntington’s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS ONE 12(3):e173872
pubmed: 28323838
pmcid: 5360242
doi: 10.1371/journal.pone.0173872
Saft C et al (2023) Symptomatic treatment options for Huntington’s disease (guidelines of the German Neurological Society). Neurol Res Pract 5(1):61
pubmed: 37968732
pmcid: 10652593
doi: 10.1186/s42466-023-00285-1
Stoker TB et al (2022) Huntington’s disease: diagnosis and management. Pract Neurol 22(1):32–41
pubmed: 34413240
doi: 10.1136/practneurol-2021-003074
Burgunder JM et al (2011) An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease. PLoS Curr 3:Rrn1260
pubmed: 21975581
pmcid: 3166256
doi: 10.1371/currents.RRN1260
Massey TH, McLauchlan DJ (2024) Huntington’s disease: A clinical primer for acute and general physicians. Clin Med 24(2):100200
doi: 10.1016/j.clinme.2024.100200
Clark ML et al (2023) A systematic review and meta-analysis of depression and apathy frequency in adult-onset Huntington’s disease. Neurosci Biobehav Rev 149:105166
pubmed: 37054804
doi: 10.1016/j.neubiorev.2023.105166
Anderson K et al (2011) An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington’s Disease. PLoS Curr 3:Rrn1261
pubmed: 21947193
pmcid: 3177175
doi: 10.1371/currents.RRN1261
Saft C et al (2023) Symptomatic treatment options for Huntington’s disease (guidelines of the German Neurological Society). Neurol Res Pract 5(1):61
pubmed: 37968732
pmcid: 10652593
doi: 10.1186/s42466-023-00285-1
Barth J et al (2013) Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Med 10(5):e1001454
pubmed: 23723742
pmcid: 3665892
doi: 10.1371/journal.pmed.1001454
Eccles FJR et al (2021) Experiences of Mindfulness-Based Cognitive Therapy for Premanifest Huntington’s Disease. J Huntingtons Dis 10(2):277–291
pubmed: 33646170
doi: 10.3233/JHD-210471
Simpson JEF, Zarotti N, for British Psychological Society (2021) Psychological interventions for people with Huntington’s disease, Parkinson’s disease, motor neurone disease, and multiple sclerosis: Evidence-based guidance. Lancaster University
Petzke TM, Rodriguez-Girondo M, van der Meer LB (2022) The Hold me Tight Program for Couples Facing Huntington’s Disease. J Huntingtons Dis 11(2):203–215
pubmed: 35466944
doi: 10.3233/JHD-210516
Jones U, Kegelmeyer DA, Kloos AD (2022) Implementing Physiotherapy Huntington’s Disease Guidelines in Clinical Practice. J Huntingtons Dis 11(3):307–311
pubmed: 35754283
doi: 10.3233/JHD-220532
Boersema-Wijma DJ et al (2023) Palliative care in advanced Huntington’s disease: a scoping review. BMC Palliat Care 22(1):54
pubmed: 37138329
pmcid: 10155365
doi: 10.1186/s12904-023-01171-y
Sokol LL et al (2023) Death Anxiety in Huntington Disease: Longitudinal Heath-Related Quality-of-Life Outcomes. J Palliat Med 26(7):907–914
pubmed: 36607769
pmcid: 10316526
doi: 10.1089/jpm.2022.0160